New discovery may lead to immunization against cardiovascular disease

Jul 31, 2008

Low levels of naturally occurring antibodies may represent an increased risk of developing cardiovascular disease, particularly stroke in men. This discovery, published in the academic journal Atherosclerosis, has now led to attempts to develop an immunization against cardiovascular disease.

Atherosclerosis (hardening of the arteries) is an inflammatory disease in which the walls of the blood vessels are thickened and become less elastic. It can cause blood clots and other cardiovascular diseases. It is not known precisely what causes atherosclerosis, but the immune system probably plays an important role. Research scientists suspect that various oxidised forms of what is known as bad cholesterol, LDL (low-density lipoprotein), contribute to the development of the disease. A research team from Karolinska Institutet, in cooperation with Lund University, has now shown that a particular type of naturally occurring antibodies, anti-PC, which are targeted against the lipid portion of the LDL molecule, play an important role in the development of cardiovascular disease.

The findings show that individuals who have low levels of anti-PC are at increased risk of cardiovascular disease. The risk is particularly high in men who develop stroke, with an almost fourfold increase.

This newly discovered risk factor, low levels of anti-PC, is independent of previously known risk factors such as high blood pressure, high blood lipids, diabetes and smoking.

"Our findings suggest that anti-PC can be used as a complement to the traditional risk factors to improve diagnosis and treatment. In addition we are currently developing anti-PC as a vaccine for atherosclerosis and cardiovascular disease," says Professor Johan Frostegård, who directed the study.

The study is based on data from 349 people who at some time over a 12-year period have suffered a heart attack or stroke and 693 individuals without symptoms of cardiovascular disease. The research has been carried out under the EU consortium CVDIMMUNE, www.cvdimmune.com/, which is led by Johan Frostegård at Karolinska Institutet.

Source: Karolinska Institutet

Explore further: Molecular method classifies patients with polycythemia vera

add to favorites email to friend print save as pdf

Related Stories

Study eyes health risks of drilling and mining in Peru

Aug 06, 2014

Duke University researchers have launched a new study to provide the first large-scale independent assessment of risks to human health and water resources from gas exploration and gold mining in one of the ...

Smartphones as a health tool for older adults

Aug 01, 2014

A team of researchers from the Universitat Politècnica de Catalunya · BarcelonaTech (UPC) and the Universitat Autònoma de Barcelona (UAB) is creating a smartphone app that will help older adults to understand ...

Recommended for you

Guidelines presented for diagnosing focal liver lesions

11 hours ago

(HealthDay)—Focal liver lesions (FLLs) are mostly benign, and can be diagnosed based on knowledge of their presentation, associated clinical and laboratory features, and natural history, according to clinical ...

Factors tied to neck, back pain improvement identified

15 hours ago

(HealthDay)—Observational registry-based research can inform patients and physicians about prognosis for subacute or chronic neck or low back pain, according to a study published in the Aug. 1 issue of ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

deatopmg
1 / 5 (1) Jul 31, 2008
There is a VERY VERY low, okay nil, probability of this EVER becoming a treatment. After this anouncement the whole subject will just vanish. There is just way to much money at stake for the medical cartel, big pharma and the medical industry, to allow this work to proceed. The cartel does it's best to keep us cronically ill and cronically treated to maximize their income.